1-6 of 6
Jose Alberto Nadal
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study

Free
Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Dimana Miteva, Veronika Pozharskaya, Xianwei Ha, Jose Alberto Nadal, Pierre Fenaux
Journal: Blood
Blood (2022) 140 (Supplement 1): 9808–9810.
https://doi.org/10.1182/blood-2022-157486
Published: 2022
Journal Articles

Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial

Free
Valeria Santini, Pierre Fenaux, Amer M. Zeidan, Rami S. Komrokji, Rena Buckstein, Esther Natalie Oliva, Xianwei Ha, Dimana Miteva, Aylin Yucel, Jose Alberto Nadal, Uwe Platzbecker
Journal: Blood
Blood (2022) 140 (Supplement 1): 4079–4081.
https://doi.org/10.1182/blood-2022-157489
Published: 2022
Journal Articles

Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study

Free
Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Esther Natalie Oliva, Veronika Pozharskaya, Xianwei Ha, Jose Alberto Nadal, Dimana Miteva, Pierre Fenaux
Journal: Blood
Blood (2022) 140 (Supplement 1): 6971–6973.
https://doi.org/10.1182/blood-2022-157487
Published: 2022
Journal Articles

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Free
Claire N. Harrison, John Mascarenhas, Pranav Abraham, Arianna Kee, Jose Alberto Nadal, Alexandrina Balanean, Ali McBride, Jonathan K. Kish, Djibril Liassou, Bruce A. Feinberg, Aaron T. Gerds
Journal: Blood
Blood (2021) 138 (Supplement 1): 3059.
https://doi.org/10.1182/blood-2021-145569
Published: 2021
Journal Articles

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

Free
John Mascarenhas, Aaron T. Gerds, Arianna Kee, Jonathan K. Kish, Pranav Abraham, Alexandrina Balanean, Jose Alberto Nadal, Djibril Liassou, Bruce A. Feinberg, Ali McBride, Claire N. Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 1980.
https://doi.org/10.1182/blood-2021-145573
Published: 2021
Journal Articles

Real-World Clinical Outcomes of Patients with Myelofibrosis Treated with Ruxolitinib: Evidence from a Multinational Medical Record Review

Free
Francesco Passamonti, Florian H. Heidel, MD, Rohan C. Parikh, Derek Tang, Betsy J. Lahue, Jose Alberto Nadal, Keith L. Davis, Mayank Ajmera, Arianna Kee, Pranav Abraham
Journal: Blood
Blood (2020) 136 (Supplement 1): 23.
https://doi.org/10.1182/blood-2020-136673
Published: 2020